Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Rhea-AI Summary
Relay Therapeutics (Nasdaq: RLAY) announced management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 10:30 a.m. ET. The session will be webcast live and an archived replay will be available for up to 30 days.
Investors can access the live and archived webcast via Relay Therapeutics’ Events page on its investor website.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
RLAY was up 6.38% while key peers were mixed: TNGX rose 5.11%, but NRIX, AVBP, IMTX, and VIR were down modestly. This pattern points to stock-specific strength rather than a broad biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 03 | Regulatory designation | Positive | +6.4% | FDA Breakthrough Therapy designation for zovegalisib plus fulvestrant in breast cancer. |
| Dec 12 | Clinical data update | Positive | +3.1% | ReDiscover subset efficacy data for zovegalisib + fulvestrant presented at SABCS 2025. |
| Nov 06 | Earnings results | Positive | -0.3% | Q3 2025 financials with reduced expenses and net loss but slight share price decline. |
| Nov 03 | Conference participation | Neutral | -2.8% | Announcement of November 2025 investor conference fireside chats and webcasts. |
| Oct 30 | Earnings date notice | Neutral | -2.7% | Scheduling notice for upcoming Q3 2025 financial results and corporate highlights. |
Recent history shows strong positive alignment to major clinical and regulatory milestones, while earnings and routine communication (conference notices, earnings dates) have often seen flat to negative price reactions.
Over the last few months, Relay Therapeutics has highlighted significant clinical and regulatory progress alongside routine corporate updates. On Feb 3, 2026, Breakthrough Therapy designation for zovegalisib coincided with a +6.38% move. Prior ReDiscover efficacy data at SABCS 2025 also aligned with a positive reaction of +3.08%. In contrast, Q3 2025 results and related earnings-date and conference announcements around Oct–Nov 2025 saw modest negative moves, underscoring that investors have reacted more favorably to major pipeline catalysts than to scheduling or earnings communications.
Market Pulse Summary
This announcement highlights Relay Therapeutics’ participation in the Guggenheim Emerging Outlook: Biotech Summit 2026, with a fireside chat on February 11, 2026 at 10:30 a.m. ET and a replay available for 30 days. The event extends visibility with investors following recent regulatory and clinical milestones. Historically, similar conference and scheduling updates have not driven major standalone price moves, with market reactions more closely tied to substantive pipeline or financial disclosures.
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 10:30 a.m. ET.
The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay's Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay's pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn.
Contact:
Pete Rahmer
prahmer@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
When will Relay Therapeutics (RLAY) present at the Guggenheim Biotech Summit 2026?
How can investors watch the Relay Therapeutics (RLAY) fireside chat on February 11, 2026?
Will Relay Therapeutics (RLAY) provide a replay of the Guggenheim Biotech Summit presentation?
What topics will Relay Therapeutics (RLAY) likely cover in the Guggenheim Biotech Summit fireside chat?
Where is information about accessing Relay Therapeutics (RLAY) presentation materials posted?
